NA 931
Alternative Names: BioGlutide; NA-931Latest Information Update: 04 Dec 2025
At a glance
- Originator Biomed Industries
- Class Neuroprotectants; Obesity therapies; Small molecules
- Mechanism of Action Gastric inhibitory polypeptide receptor agonists; Glucagon receptor agonists; Glucagon-like peptide-1 receptor agonists; Insulin-like growth factor I stimulants
-
Orphan Drug Status
No
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Phase II Obesity
- Preclinical Alcoholism
Most Recent Events
- 27 Jul 2025 Updated efficacy and adverse event data from a phase I trial in Obesity released at the Alzheimer's Association International Conference 2025 (AAIC-2025)
- 12 Jul 2025 Efficacy and adverse events data from a phase II trial in Obesity presented at the 107th Annual Meeting of the Endocrine Society (ENDO-2025)
- 23 Jun 2025 Efficacy and adverse event data from phase II trial in Obesity released by Biomed Industries